HSIL acquires majority stake in Lifesenz Cancer Research Labs
Mumbai, June 10 -- Hemant Surgical Industries has completed the strategic acquisition of a majority stake (66.66%) in Lifesenz Cancer Research Labs (Lifesenz), a company focused on precision oncology and personalized cancer treatment solutions for an amount of Rs. 19.98 crore, making Lifesenz a subsidiary of the Company with effect from 01 June 2026.
Published by HT Digital Content Services with permission from Capital Market....
Click here to read full article from source
इस लेख के रीप्रिंट को खरीदने या इस प्रकाशन का पूरा फ़ीड प्राप्त करने के लिए, कृपया
हमे संपर्क करें.